ERBB4 and schizophrenia: Mutations of the ERBB4 gene differentially affected the treatment response to paliperidone in individuals with schizophrenia, implicating the neuregulin 1 (NRG1)–ErbB4 pathway for modulating the antipsychotic response (Wang et al., 2015).